ArticleMediterranean journal of rheumatology2018
Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug.
Article in Mediterranean journal of rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Association Between Charlson Comorbidity Index and Pressure Injury Stage: A Retrospective Cohort Study.International wound journal · 2026Article
- Mediterranean Journal of Rheumatology March 2018 Highlights.Mediterranean journal of rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids (GC) have been used for more than 70 years in the management of rheumatoid arthritis (RA). The immediate improvement of the clinical picture is one of their main advantages. However, RA is a chronic disease and unfortunately, long-term GC administration is associated with several serious adverse events. This is the major reason why GC therapy should be administered for the shortest possible period of time, with tapering as far as it is feasible. Although this is accepted as a "dogma", there is recently growing evidence suggesting that low doses, even in the long-term, might not be as dangerous as previously believed. On the contrary, GC may be beneficial for RA patients in several ways, considering their protective role in radiographic progression or lymphoma development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.